Rejuvenare - I don't have time to wait for approval in the US Patient Jerry relates why he chose Rejuvenare stem cell therapy to treat Parkinson's outside the US. Although he'd earlier been successful keeping the disease's progression slowed, they were no longer effective for him and he was told it would be about 10 years before this procedure was approved in the USFrom:rejuvenareViews:0 0ratingsTime:01:24More inEducation Originally posted here: Rejuvenare - I don't have time to wait for approval in the US - Video … Continue reading →

Rejuvenare - I don't have time to wait for approval in the US Patient Jerry relates why he chose Rejuvenare stem cell therapy to treat Parkinson's outside the US. Although he'd earlier been successful keeping the disease's progression slowed, they were no longer effective for him and he was told it would be about 10 years before this procedure was approved in the USFrom:rejuvenareViews:0 0ratingsTime:01:24More inEducation Originally posted here: Rejuvenare - I don't have time to wait for approval in the US - Video … Continue reading →

Rejuvenare stem cell treatment for stroke.mov Rejuvenare CEO Carlo Velarde relates how his mother, completely incapacitated by a crippling stroke, has regained her quality of life, her mobility, her thought process after undergoing stem cell therapy for stroke.From:rejuvenareViews:0 0ratingsTime:00:47More inEducation See the article here: Rejuvenare stem cell treatment for stroke.mov - Video … Continue reading →

The Rejuvenare Experience .mov Patient Jerry and his wife discuss their Rejuvenare experience in Jerry receiving stem cell therapy for Parkinson's disease. They are very impressed with how fantastic the experience has been and wonders how Rejuvenare can offer such excellent services to its patient clients.From:rejuvenareViews:0 0ratingsTime:01:11More inEducation More here: The Rejuvenare Experience .mov - Video … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (OPXA), a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Health Canada has approved the Company's Clinical Trial Application (CTA). The application was filed with the Biologics and Genetic Therapies Directorate. With this approval by the Canadian Health Authority, Opexa expects to expand its ongoing clinical trial in Secondary Progressive MS (SPMS) patients to include several sites in Canada. The Abili-T trial, a Phase 2b study of Tcelna in subjects with SPMS, is currently enrolling patients in the United States. To date, over a half of the clinical sites have been initiated and approximately ten percent of subjects have been enrolled. Enthusiasm and support remains strong among the patients and the treatment sites. The trial is expected to enroll 180 patients in approximately 30 sites in the U.S. and Canada and conclude in 2015. In addition, at the end of September, The United States Adopted Names Council (USANC) officially adopted Tcelnas non-proprietary name, imilecleucel-T. USANC is tri-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association. USANC aims to standardize drug nomenclature by selecting informative and unique non-proprietary names for all … Continue reading →

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (CYTX) announced this morning that a peer-reviewed case series using Cytoris cell therapy to treat patients suffering from complex cryptoglandular fistula has been published in the current issue of the British Medical Journal: Case Reports. The patients were treated by Dr. David Borowski and Dr. Pud Bhaskar, Consultant Surgeons at the University Hospital of North Tees, a National Health Service (NHS) hospital in the United Kingdom. In this case series, three patients suffering from long-standing complex cryptoglandular fistula-in-ano were treated using fat grafts enriched with their own adipose-derived stem and regenerative cells (ADRCs), processed using Cytoris Celution system. The ADRC-enriched graft was injected directly into the tissue surrounding the fistula to close the fistula track. The interior opening of the fistula was closed with a mucosal advancement flap. All three patients remain fully healed at two to three year follow-up, with one patient undergoing colostomy reversal to restore bowel continuity. These three patients are the initial cases treated within a phase I feasibility study; all three had been suffering from the symptoms of their fistulae with considerable reduction in their ability to lead a normal life, said Dr. Borowski. Other treatments had failed, and the … Continue reading →

JERUSALEM--(BUSINESS WIRE)-- Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina. Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need. SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor. Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have … Continue reading →